NFV NEWS

TMCNet:  Research and Markets: Global Cariprazine Use for Schizophrenia - Forecast and Market Analysis to 2022

[April 14, 2014]

Research and Markets: Global Cariprazine Use for Schizophrenia - Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/5z4vzf/cariprazine) has announced the addition of the "Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.

Cariprazine is a D3-preferring D3/D2 receptor partial agonist under development for the treatment of schizophrenia, bipolar mania, and major depressive disorder by Hungary-based Gedeon Richter and Forest. While maintainig highest affinity for D3 receptors, cariprazine also has low potency at 5-HT2C, H1, and adrenergic receptor sites.

Scope

  • Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cariprazine for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Key Topics Covered:

  1. Tables & Figures
  2. Introduction
  3. Disease Overview
  4. Disease Management
  5. Competitive Assessment
  6. Opportunity and Unmet Need
  7. Pipeline Assessment
  8. Cariprazine
  9. Appendix

For more information visit http://www.researchandmarkets.com/research/5z4vzf/cariprazine


[ Back To NFVZone's Homepage ]